06:33 , Aug 10, 2018 |  BC Week In Review  |  Financial News

SQZ raises $72M series C

Cell therapy company SQZ Biotechnologies Co. (Watertown, Mass.) raised $72 million on Aug. 8 in an oversubscribed, untranched series C round. New investors Everblue, Illumina Ventures, Invus, Orient Life and Viva Ventures Biotech Group participated,...
12:33 , Aug 8, 2018 |  BC Extra  |  Financial News

SQZ raises $72M series C

Cell therapy company SQZ Biotechnologies Co. (Watertown, Mass.) raised $72 million in an oversubscribed, untranched series C round. New investors Everblue, Illumina Ventures, Invus, Orient Life and Viva Ventures Biotech Group participated, as did existing...
01:34 , Jun 22, 2018 |  BC Innovations  |  Targets & Mechanisms

T cell balancing act

Among the improvements to next-generation CAR T cell therapies is the need to optimize the ratios of the different T cell subsets. While CD8+ T cells have grabbed most of the attention, a study from...
20:12 , Feb 9, 2018 |  BC Week In Review  |  Company News

Advanced Proteome, ImmunoBiochem to develop ADCs for TNBC

Advanced Proteome Therapeutics Corp. (TSX-V:APC; FSE:0E8) and ImmunoBiochem Corp. (Toronto, Ontario) will evaluate combining an undisclosed antibody from ImmunoBiochem with Advanced Proteome's site-selective conjugation technology to develop antibody-drug conjugates (ADCs) to treat triple-negative breast cancer...
16:16 , Feb 9, 2018 |  BC Week In Review  |  Clinical News

ZZ Biotech's 3K3A-APC reduces hemorrhage rate in Phase II for acute ischemic stroke

ZZ Biotech LLC (Houston, Texas) reported preliminary data from the Phase II RHAPSODY trial in 110 patients with moderate to severe acute ischemic stroke who were treated with IV tissue plasminogen activator (tPA), intra-arterial thrombectomy...
17:34 , Jun 2, 2017 |  BioCentury  |  Emerging Company Profile

Prolonging thrombin production

ApcinteX Ltd. is betting that inhibiting an endogenous brake on thrombin production will generate a therapy for hemophilia A and B that can be used by patients who have developed neutralizing antibodies to factor replacement...
02:42 , Feb 11, 2017 |  BioCentury  |  Finance

Dynamic duo

The asset-centric model of venture investing often sees a VC working with a stable of serial entrepreneurs who are deployed to new companies when the ones they have founded or helmed are sold. But few...
13:36 , Feb 9, 2017 |  BC Extra  |  Financial News

SuperX raises $11M series A round

Anticoagulation play SuperX Ltd. (Cambridge, U.K.) raised $11 million in a series A round led by Medicxi. Johnson & Johnson Innovation-JJDC Inc. also participated. The newco is developing preclinical antibodies against an undisclosed target to...
21:05 , Jan 27, 2017 |  BC Week In Review  |  Clinical News

Colonic-release linaclotide: Ph IIb data

Top-line data from a double-blind, U.S. Phase IIb trial in 532 adult patients with IBS-C showed that once-daily 300 µg oral colonic-release-1 formulation of linaclotide (CR1) for 12 weeks led to a greater proportion of...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Company News

University of Toronto, Advanced Proteome Therapeutics deal

The university’s Toronto Recombinant Antibody Centre (TRAC) granted Advanced Proteome an exclusive option to license preclinical oncology antibody candidates against an undisclosed target to develop antibody-drug conjugates (ADCs) using Advanced Proteome’s protein conjugation technology. The...